Health TrialsbyHealthPanel

REGistry of Long-term AnTithrombotic TherApy-2

ConditionAtrial Fibrillation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation

About this trial

To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Documented atrial fibrillation with CHA2DS2VASC > 1

Disqualifiers

Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine > 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention

Trial population

Hospitalized or outpatients with confirmed atrial fibrillation and CHA2DS2VASC \> 1

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Anticoagulants

    Drug

    oral anticoagulants, dual or triple antithrombotic theraphy

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

composite of major cardiovascular events

stroke, myocardial infarction, stent thrombosis \[definite or probable\], or urgent revascularization, cqrdiac death

Time frame
unclusion up to 5 years
2

composite of any bleeding events

major, clinically relevant nonmajor, minor (BARC, ISTH,GARFIELD AF)

Time frame
unclusion up to 5 years

Secondary outcomes

1

Mutations in following genes

CYP2C9\*, VKORC1

Time frame
inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Lead sponsor

Source ClinicalTrials.gov
Apply now